Cargando…

Acquired mechanisms of immune escape in cancer following immunotherapy

Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryan Iorgulescu, J., Braun, David, Oliveira, Giacomo, Keskin, Derin B., Wu, Catherine J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249768/ https://www.ncbi.nlm.nih.gov/pubmed/30466478 http://dx.doi.org/10.1186/s13073-018-0598-2

Ejemplares similares

Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism
por: Bachmann, Martin F., et al.
Publicado: (2022)

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape
por: Bruschini, Sara, et al.
Publicado: (2020)

Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape
por: Yi, Chunyan, et al.
Publicado: (2022)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
por: Vanichapol, Thitinee, et al.
Publicado: (2018)

Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
por: Aktar, Nasrin, et al.
Publicado: (2022)

Revisiting immune escape in colorectal cancer in the era of immunotherapy
por: Ijsselsteijn, Marieke Erica, et al.
Publicado: (2019)

The Assassination of Lincoln and the Escape and Death of Booth
Publicado: (1940)

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020)

Bioengineering of bacteria for cancer immunotherapy
por: Nguyen, Dinh-Huy, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
por: Hanley, Christopher J., et al.
Publicado: (2020)

Quantifying the RSV immunity debt following COVID-19: a public health matter
por: Billard, Marie-Noëlle, et al.
Publicado: (2022)

T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all
por: Gaudeaux, P., et al.
Publicado: (2022)

Ferroptosis: a new approach for immunotherapy
por: Zeng, Chong, et al.
Publicado: (2020)

Cancer immunotherapy comes of age and looks for maturity
por: Finck, Amanda, et al.
Publicado: (2020)

Immunotherapy in COVID-19: why, who, and when?
por: Sinha, Pratik, et al.
Publicado: (2021)

Host-targeted approaches to sepsis due to community-acquired pneumonia
por: Cilloniz, Catia, et al.
Publicado: (2022)

Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
por: Bodmer, Walter
Publicado: (2022)

Immunotherapies for COVID-19: lessons learned from sepsis
por: Remy, Kenneth E, et al.
Publicado: (2020)

From macrophage biology to macrophage-based cellular immunotherapies
por: Mass, Elvira, et al.
Publicado: (2021)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Towards evidence-based response criteria for cancer immunotherapy
por: Garralda, Elena, et al.
Publicado: (2023)

Cutaneous vasculitis following COVID-19 vaccination
por: Cavalli, Giulio, et al.
Publicado: (2021)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
por: Sapoznik, Sivan, et al.
Publicado: (2012)

COVID-19 vaccination and cancer immunotherapy: should they stick together?
por: Brest, Patrick, et al.
Publicado: (2021)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

COVID-19 vaccine design: the Janus face of immune enhancement
por: Hotez, Peter J., et al.
Publicado: (2020)

Comment on Laratta et al. Marital Stability and Quality of Couple Relationships after Acquired Brain Injury: A Two-Year Follow-Up Clinical Study. Healthcare 2021, 9, 283
por: van den Broek, Brenda, et al.
Publicado: (2021)

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
por: Khan, Zia, et al.
Publicado: (2019)

Immunogenic cell death and immunogenic surrender: related but distinct mechanisms of immune surveillance
por: Mezzapelle, Rosanna, et al.
Publicado: (2021)

The Immune Escape Mechanisms of Mycobacterium Tuberculosis
por: Zhai, Weijie, et al.
Publicado: (2019)

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
por: Hu, Xiaoqian, et al.
Publicado: (2023)

Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
por: Mestrallet, Guillaume, et al.
Publicado: (2023)

The host response in different aetiologies of community-acquired pneumonia: Potential new targets for adjunctive treatments?
por: Vestergaard Jensen, Andreas
Publicado: (2022)

Does SARS-CoV-2vaccination induce acquired autoimmune discords and inflammatory manifestations?
por: Bahrini, Khadija, et al.
Publicado: (2023)

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy
por: Garaud, Soizic, et al.
Publicado: (2022)

Precision intervention of cell type-specific targeting is required for future cancer immunotherapy
por: Cai, Yitong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fvairja234d2tvmsar6h3mi3c4